Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.090
-0.010 (-0.91%)
At close: Nov 22, 2024, 4:00 PM
1.110
+0.020 (1.83%)
After-hours: Nov 22, 2024, 7:59 PM EST
Coherus BioSciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 304.34 | 257.24 | 211.04 | 326.55 | 475.82 | 356.07 | Upgrade
|
| Revenue | 304.34 | 257.24 | 211.04 | 326.55 | 475.82 | 356.07 | Upgrade
|
| Revenue Growth (YoY) | 44.19% | 21.89% | -35.37% | -31.37% | 33.63% | - | Upgrade
|
| Cost of Revenue | 168.26 | 158.99 | 70.08 | 57.59 | 37.67 | 17.08 | Upgrade
|
| Gross Profit | 136.08 | 98.25 | 140.96 | 268.96 | 438.16 | 338.99 | Upgrade
|
| Selling, General & Admin | 163.44 | 185.62 | 198.48 | 169.71 | 139.08 | 137.04 | Upgrade
|
| Research & Development | 94.87 | 105.84 | 199.36 | 363.11 | 142.76 | 94.19 | Upgrade
|
| Operating Expenses | 258.3 | 291.45 | 397.84 | 532.82 | 281.84 | 231.23 | Upgrade
|
| Operating Income | -122.23 | -193.2 | -256.88 | -263.86 | 156.32 | 107.77 | Upgrade
|
| Interest Expense | -32.43 | -40.54 | -32.47 | -22.96 | -21.17 | -17.6 | Upgrade
|
| Interest & Investment Income | 2.8 | 2.8 | 1.9 | 1.4 | 0.6 | 1.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 180.14 | 2.67 | 1.92 | -1.68 | -0.05 | 1.01 | Upgrade
|
| EBT Excluding Unusual Items | 28.28 | -228.27 | -285.53 | -287.1 | 135.71 | 92.78 | Upgrade
|
| Merger & Restructuring Charges | -5.5 | -10 | - | - | - | - | Upgrade
|
| Asset Writedown | -10.6 | - | - | - | - | - | Upgrade
|
| Other Unusual Items | -12.63 | - | -6.22 | - | - | - | Upgrade
|
| Pretax Income | -0.45 | -238.27 | -291.75 | -287.1 | 135.71 | 92.78 | Upgrade
|
| Income Tax Expense | - | -0.38 | - | - | 3.46 | 2.94 | Upgrade
|
| Earnings From Continuing Operations | -0.45 | -237.89 | -291.75 | -287.1 | 132.24 | 89.83 | Upgrade
|
| Net Income | -0.45 | -237.89 | -291.75 | -287.1 | 132.24 | 89.83 | Upgrade
|
| Net Income to Common | -0.45 | -237.89 | -291.75 | -287.1 | 132.24 | 89.83 | Upgrade
|
| Net Income Growth | - | - | - | - | 47.21% | - | Upgrade
|
| Shares Outstanding (Basic) | 114 | 94 | 78 | 75 | 71 | 70 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 94 | 78 | 75 | 83 | 73 | Upgrade
|
| Shares Change (YoY) | 32.62% | 21.30% | 2.89% | -9.63% | 14.08% | 12.53% | Upgrade
|
| EPS (Basic) | -0.00 | -2.53 | -3.76 | -3.81 | 1.85 | 1.29 | Upgrade
|
| EPS (Diluted) | -0.00 | -2.53 | -3.76 | -3.81 | 1.62 | 1.23 | Upgrade
|
| EPS Growth | - | - | - | - | 31.99% | - | Upgrade
|
| Free Cash Flow | -62.27 | -175.17 | -243.16 | -38.72 | 146.91 | 26.53 | Upgrade
|
| Free Cash Flow Per Share | -0.55 | -1.86 | -3.13 | -0.51 | 1.76 | 0.36 | Upgrade
|
| Gross Margin | 44.71% | 38.19% | 66.79% | 82.36% | 92.08% | 95.20% | Upgrade
|
| Operating Margin | -40.16% | -75.10% | -121.72% | -80.80% | 32.85% | 30.27% | Upgrade
|
| Profit Margin | -0.15% | -92.48% | -138.24% | -87.92% | 27.79% | 25.23% | Upgrade
|
| Free Cash Flow Margin | -20.46% | -68.09% | -115.22% | -11.86% | 30.88% | 7.45% | Upgrade
|
| EBITDA | -116.92 | -189.41 | -253.18 | -260.4 | 159.21 | 111.03 | Upgrade
|
| EBITDA Margin | -38.42% | -73.63% | -119.97% | -79.74% | 33.46% | 31.18% | Upgrade
|
| D&A For EBITDA | 5.31 | 3.79 | 3.7 | 3.45 | 2.89 | 3.26 | Upgrade
|
| EBIT | -122.23 | -193.2 | -256.88 | -263.86 | 156.32 | 107.77 | Upgrade
|
| EBIT Margin | -40.16% | -75.10% | -121.72% | -80.80% | 32.85% | 30.27% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 2.55% | 3.17% | Upgrade
|
| Advertising Expenses | - | - | - | - | 3.8 | 4.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.